{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:06:14Z","timestamp":1793300774225,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"am","delay-in-days":306,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jiac.2022.03.020","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T07:43:19Z","timestamp":1650267799000},"page":"1172-1176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-term use of tedizolid for pulmonary nocardiosis"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8498-8583","authenticated-orcid":false,"given":"Yuri","family":"Chomei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2022.03.020_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1128\/CMR.7.2.213","article-title":"Nocardia species: host-parasite relationships","volume":"7","author":"Beaman","year":"1994","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiac.2022.03.020_bib2","author":"LPSN"},{"key":"10.1016\/j.jiac.2022.03.020_bib3","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1086\/657399","article-title":"Antimicrobial-resistant nocardia isolates, United States, 1995-2004","volume":"51","author":"Uhde","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.03.020_bib4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/AAC.02770-14","article-title":"Antimicrobial susceptibility among clinical Nocardia species identified by multilocus sequence analysis","volume":"59","author":"McTaggart","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2022.03.020_bib5","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/clinids\/22.6.891","article-title":"Nocardiosis","volume":"22","author":"Lerner","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.03.020_bib6","series-title":"M24 susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes","first-page":"45","author":"Gail","year":"2018"},{"key":"10.1016\/j.jiac.2022.03.020_bib7","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1517\/17425255.2015.1098617","article-title":"Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones","volume":"11","author":"Douros","year":"2015","journal-title":"Expet Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.jiac.2022.03.020_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01537-17","article-title":"In vitro susceptibility testing of tedizolid against isolates of nocardia","volume":"61","author":"Brown-Elliott","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2022.03.020_bib9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/phar.1337","article-title":"Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug","volume":"34","author":"Flanagan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2022.03.020_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2022.03.020_bib11","article-title":"Tedizolid versus linezolid for the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis","volume":"8","author":"Lan","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jiac.2022.03.020_bib12","doi-asserted-by":"crossref","first-page":"e710","DOI":"10.1093\/cid\/ciab032","article-title":"A phase 3, randomized, double-blind study comparing tedizolid phosphate and linezolid for treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia","volume":"73","author":"Wunderink","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.03.020_bib13","doi-asserted-by":"crossref","first-page":"100261","DOI":"10.1016\/j.jctube.2021.100261","article-title":"Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection","volume":"24","author":"Shaw","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.jiac.2022.03.020_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jac\/dkw484","article-title":"Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity","volume":"72","author":"Yuste","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2022.03.020_bib15","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1093\/jac\/dkz216","article-title":"Efficacy and safety of long-term use of tedizolid after liver transplantation in an adolescent with pulmonary tuberculosis","volume":"74","author":"Yuste","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2022.03.020_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00356-20","article-title":"Safety and tolerability of more than six days of tedizolid treatment","volume":"64","author":"Mensa Vendrell","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2022.03.020_bib17","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1473-3099(04)01109-0","article-title":"Peripheral neuropathy associated with prolonged use of linezolid","volume":"4","author":"Bressler","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2022.03.020_bib18","first-page":"61","article-title":"Optic neuropathy associated with linezolid: systematic review of cases","volume":"43","author":"Brandariz-N\u00fa\u00f1ez","year":"2019","journal-title":"Farm Hosp"},{"key":"10.1016\/j.jiac.2022.03.020_bib19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1128\/AAC.03684-14","article-title":"Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function","volume":"59","author":"Flanagan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2022.03.020_bib20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40265-015-0352-7","article-title":"Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens","volume":"75","author":"Zhanel","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jiac.2022.03.020_bib21","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/jac\/dkw206","article-title":"Characterization of the haematological profile of 21 days of tedizolid in healthy subjects","volume":"71","author":"Lodise","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2022.03.020_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa090","article-title":"Safety and outcomes of linezolid use for nocardiosis","volume":"7","author":"Davidson","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2022.03.020_bib23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MAJ.0b013e31822cb5dc","article-title":"Clinical spectrum and outcome of Nocardia infection: experience of 15-year period from a single tertiary medical center","volume":"343","author":"Hardak","year":"2012","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jiac.2022.03.020_bib24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1086\/345907","article-title":"Clinical experience with linezolid for the treatment of nocardia infection","volume":"36","author":"Moylett","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.03.020_bib25","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ijantimicag.2016.11.032","article-title":"Myelosuppression-sparing treatment of central nervous system nocardiosis in a multiple myeloma patient utilizing a tedizolid-based regimen: a case report","volume":"49","author":"Matin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2022.03.020_bib26","first-page":"208","article-title":"Pulmonary nocardiosis treated with tedizolid","volume":"43","author":"Gim\u00e9nez-Arufe","year":"2019","journal-title":"Farm Hosp"},{"key":"10.1016\/j.jiac.2022.03.020_bib27","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s10096-021-04186-6","article-title":"Long-term use of liposomal nebulized amikacin and tedizolid for the treatment of disseminated nocardiosis after allogeneic hematopoietic stem cell transplantation","volume":"40","author":"Soueges","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2200099X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2200099X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:05:47Z","timestamp":1761159947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X2200099X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1341321X2200099X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2022.03.020","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term use of tedizolid for pulmonary nocardiosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2022.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}